- Home
- NXG vs CGEN Comparison
NXG vs CGEN Comparison
Compare NXG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXG
- CGEN
- Stock Information
- Founded
- NXG 2012
- CGEN 1993
- Country
- NXG United States
- CGEN Israel
- Employees
- NXG N/A
- CGEN N/A
- Industry
- NXG
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXG
- CGEN Health Care
- Exchange
- NXG Nasdaq
- CGEN Nasdaq
- Market Cap
- NXG 163.3M
- CGEN 149.6M
- IPO Year
- NXG N/A
- CGEN 2000
- Fundamental
- Price
- NXG $46.94
- CGEN $1.41
- Analyst Decision
- NXG
- CGEN Strong Buy
- Analyst Count
- NXG 0
- CGEN 1
- Target Price
- NXG N/A
- CGEN $4.00
- AVG Volume (30 Days)
- NXG 24.4K
- CGEN 264.2K
- Earning Date
- NXG 01-01-0001
- CGEN 05-19-2025
- Dividend Yield
- NXG 14.78%
- CGEN N/A
- EPS Growth
- NXG N/A
- CGEN N/A
- EPS
- NXG N/A
- CGEN N/A
- Revenue
- NXG N/A
- CGEN $27,864,000.00
- Revenue This Year
- NXG N/A
- CGEN $11.81
- Revenue Next Year
- NXG N/A
- CGEN $28.37
- P/E Ratio
- NXG N/A
- CGEN N/A
- Revenue Growth
- NXG N/A
- CGEN N/A
- 52 Week Low
- NXG $30.32
- CGEN $1.35
- 52 Week High
- NXG $42.29
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- NXG 44.31
- CGEN 29.77
- Support Level
- NXG $46.58
- CGEN $1.50
- Resistance Level
- NXG $49.30
- CGEN $1.65
- Average True Range (ATR)
- NXG 1.19
- CGEN 0.06
- MACD
- NXG -0.05
- CGEN -0.00
- Stochastic Oscillator
- NXG 20.54
- CGEN 3.45
About NXG NXG NextGen Infrastructure Income Fund of Beneficial Interest
Cushing NextGen Infrastructure Income Fund is a closed-end investment management company. Its investment objective is to seek a high total return with a focus on current income. The Fund invests at least 80% of its net assets in a portfolio of equity and debt securities of infrastructure companies, including energy infrastructure companies, industrial infrastructure companies, sustainable infrastructure companies, and technology & communication infrastructure companies.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.